FDA.gov / Regulations.gov (2024) 10
introduced two shrimp hypoallergens, MEM49 and MED171, and evaluated their effectiveness as DNA vaccines in reducing shellfish allergy symptoms in mice
It was marked
Keep a symptom diary noting the timing, severity, and location of joint pain, along with any potential triggers or relieving factors
Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)
This may include managing side effects, improving digestion and energy, supporting healthy blood sugar, maintaining muscle, staying hydrated, choosing meals and supplements, and addressing sleep, inflammation, stress eating, and other nutrition concerns